Squarepoint
ALXN

Squarepoint’s Alexion Pharmaceuticals ALXN Stock Holding History

Squarepoint’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-69,002
Closed -$12.7M – 3747
2021
Q2 		$12.7M Sell
69,002
-25,223
-27% -$4.33M 0.05% 379
2021
Q1 		$14.4M Buy
94,225
+58,136
+161% +$8.99M 0.08% 272
2020
Q4 		$5.64M Buy
+36,089
New +$4.64M 0.04% 441
2020
Q3 		– Sell
-113,165
Closed -$12.7M – 2993
2020
Q2 		$12.7M Buy
113,165
+45,334
+67% +$4.81M 0.21% 121
2020
Q1 		$6.09M Sell
67,831
-34,239
-34% -$3.36M 0.16% 152
2019
Q4 		$11M Sell
102,070
-133,899
-57% -$14.3M 0.07% 270
2019
Q3 		$23.1M Buy
235,969
+178,839
+313% +$20.2M 0.21% 115
2019
Q2 		$7.48M Buy
+57,130
New +$7.36M 0.07% 321
2019
Q1 		– Sell
-69,327
Closed -$6.75M – 2545
2018
Q4 		$6.75M Buy
69,327
+15,824
+30% +$1.87M 0.08% 331
2018
Q3 		$7.44M Buy
53,503
+18,530
+53% +$2.32M 0.09% 299
2018
Q2 		$4.34M Sell
34,973
-66,674
-66% -$7.79M 0.06% 433
2018
Q1 		$11.3M Buy
+101,647
New +$12.1M 0.18% 150
2017
Q4 		– Sell
-102,262
Closed -$14.3M – 2425
2017
Q3 		$14.3M Buy
+102,262
New +$13.9M 0.28% 78
2017
Q2 		– Sell
-16,132
Closed -$1.96M – 1917
2017
Q1 		$1.96M Buy
+16,132
New +$2.08M 0.05% 394
2016
Q3 		– Sell
-16,574
Closed -$1.94M – 1357
2016
Q2 		$1.94M Buy
16,574
+14,199
+598% +$2.01M 0.12% 201
2016
Q1 		$331K Buy
+2,375
New +$349K 0.03% 789
2015
Q1 		– Sell
-3,100
Closed -$574K – 506
2014
Q4 		$574K Buy
+3,100
New +$574K 0.56% 59

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Squarepoint's ALXN Position: Q3 2021 in Review

Squarepoint sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 69,002 shares — an estimated $12.7M sold.

Squarepoint first reported a position in ALXN in Q4 2014 and held it in 17 quarters. The position peaked at $23.1M in Q3 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Squarepoint reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Squarepoint sold 69,002 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12.7M.
  • Squarepoint first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 17 quarters.
  • Squarepoint's Alexion Pharmaceuticals position peaked at $23.1M in Q3 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.